Sonosine Secures £219.7k Pre-Seed Funding to Advance Mobile Medical Imaging Technology

Newbury based deep tech company Sonosine Limited has raised £219.7k in a pre-seed funding round to further develop its innovative medical imaging diagnostic tool. The latest capital injection gives the University of Oxford spin out an estimated post-money valuation of £1.7m.

Incorporated in August 2015, Sonosine is developing the Pulsar 1, a medical imaging scanner that utilises patented Electro Magnetic Acoustic technology. By combining radio signals and ultrasound, the device provides high-quality diagnostic images that offer greater clarity than traditional ultrasound alone. The company is targeting clinicians and medical specialists in primary care, sports medicine, trauma, and orthopaedics.

The core problem Sonosine aims to solve is the high cost and lack of mobility associated with traditional MRI and CT scanners. By providing an affordable and mobile alternative, the Pulsar 1 enables clinicians to conduct effective on-the-spot diagnoses. This approach removes the need for costly medical imaging centre referrals and invasive procedures, improving the patient experience and accelerating clinical decision making. The company also maintains a broader mission to make advanced medical imaging accessible in hard to reach communities and less developed countries.

Operating from its headquarters at the Begbroke Science Park, the company remains in its research and development phase. Latest financial filings show a loss of £371,161, which is typical for a hardware focused deep tech firm navigating the lengthy regulatory and clinical testing pathways of the medical device industry. The company currently operates with a lean team of between four and eight employees.

The recent pre-seed round, allotted on 3 March 2026 and filed on 11 March 2026, brings in an estimated £219.7k. While the specific investors for this allotment were not named in the latest filing, Sonosine has historically been backed by the University of Oxford alongside various institutional and private investors. The company previously secured over £2.2m in early stage seed funding to secure its worldwide patents and develop lab prototypes. This new £1.7m valuation round acts as a strategic capital injection as the company pushes toward commercialisation and seeks to put its devices into the hands of medical specialists.

This funding arrives during a transformative period for the United Kingdom health tech and medical device sectors. Despite broader venture capital slowdowns in other industries, the domestic medical technology market has demonstrated remarkable resilience. Industry forecasts project the United Kingdom medical technology market will reach £15.7 billion in value by the end of 2025, growing to £20.5 billion by 2030.

A significant driver of this growth is institutional demand from the National Health Service, which is actively seeking innovations that can shift care from acute hospital settings into primary care and the community. Technologies that offer mobile, point of care diagnostics are particularly attractive to investors, as they align with government policy shifts aimed at reducing waiting lists and streamlining patient pathways. Sonosine fits squarely into this category, leveraging its deep technical expertise to decentralise medical imaging and reduce the systemic burden on specialised diagnostic centres.